Actively Recruiting
[18F]NIDF PET Imaging in Tau-related Diseases
Led by Tianjin Medical University · Updated on 2025-12-29
20
Participants Needed
2
Research Sites
265 weeks
Total Duration
On this page
Sponsors
T
Tianjin Medical University
Lead Sponsor
T
Tianjin Medical University General Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
In the field of diagnosing brain neurodegenerative diseases, it is now a well-established practice to inject positron-emitting tracers into the human body. These tracers bind to specific target proteins, allowing their distribution to be visualized via PET imaging. Currently, several research groups worldwide are engaged in developing and clinically validating their own tau imaging agents. This clinical research project aims to visualize abnormal tau pathology in the living human brain using \[18F\]NIDF PET imaging. \[18F\]NIDF is a 2-arene-azaindole-based tracer that offers stronger binding affinity to tau neurofibrillary tangles and reduced non-specific/off-target binding compared to existing tau-PET imaging agents. The study primarily focuses on evaluating the safety and diagnostic efficacy of \[18F\]NIDF PET imaging in human subjects.
CONDITIONS
Official Title
[18F]NIDF PET Imaging in Tau-related Diseases
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Between 18 and 90 years old
- No gender limitation
- Clinical diagnosis supporting neurodegeneration with no other neurological diseases
- Healthy participants or patients with probable Alzheimer's disease or dementia due to other causes
- Signed informed consent by the participant or their legal guardian or caregiver
You will not qualify if you...
- Allergy to [18F]NIDF or any of its excipients
- Unable to provide written informed consent and no legal representative available
- Unwilling or unable to undergo PET scan tracer injections
- Conditions increasing risk or limiting ability to tolerate procedures (e.g., renal or liver failure, advanced cancer)
- Received experimental drug or device within 1 month
- Other serious neurological, gastrointestinal, cardiovascular, liver, kidney, blood, tumor, endocrine, respiratory, immune deficiency, or other serious diseases
- Women who are currently pregnant or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
The First Affiliated Hospital of University of Science and Technology of China
Hefei, Anhui, China, 230000
Actively Recruiting
2
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China, 350005
Actively Recruiting
Research Team
Y
Ying Wang, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here